



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/02 (2006.01)
A61K 31/495 (2006.01) C07K 16/30 (2006.01)

(21) International Application Number:

PCT/US2024/052038

(22) International Filing Date:

18 October 2024 (18.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/591,589 19 October 2023 (19.10.2023) US
63/562,397 07 March 2024 (07.03.2024) US

(71) Applicant: **PURETECH LYT, INC.** [US/US]; 6 Tide Street, Suite 400, Boston, Massachusetts 02210 (US).

(72) Inventors: **FILIPOVIC, Aleksandra**; c/o PureTech LYT, Inc., 6 Tide Street, Suite 400, Boston, Massachusetts 02210 (US). **KORTH, Christopher C.**; c/o PureTech LYT, Inc., 6 Tide Street, Suite 400, Boston, Massachusetts 02210 (US).

KROP, Julie Swartzman; c/o PureTech LYT, Inc., 6 Tide Street, Suite 400, Boston, Massachusetts 02210 (US).

(74) Agent: **CHEN, Yahua**; c/o Mintz Levin, One Financial Center, Boston, Massachusetts 02111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH ANTIBODIES INHIBITING GALECTIN-9

Part 1 (Single Agent)

LYT-200 Dose Finding (4+2 Design)
Patients with **relapsed/refractory** AML and high Risk MDS
Safety, tolerability, Minimum Safe and Biological Dose, RP2D PK/PD, Immunogenicity

Dose Levels
Cohort 1_2.0 mg/kg IV QW (up to n=6)
Cohort 2_4.0 mg/kg IV QW (up to n=6)
Cohort 3_7.5 mg/kg IV QW (up to n=6)
Cohort 4_12.0 mg/kg IV QW (up to n=6)
Cohort 5_16.0 mg/kg IV QW (up to n=6)

Up to 50 Patients with Backfill of 4 to 6 Patients per Cohort

Part 2 (Combo)

-Venetoclax
-Azacytidine
Or
-Decitabine

LYT-200 Dose Finding (4+2 Design)
Patients with **relapsed/refractory** AML and high Risk MDS
Safety, tolerability, Minimum Safe and Biological Dose, RP2D PK/PD, Immunogenicity

Dose Levels
Cohort 1_4.0 mg/kg IV QW (up to n=6)
Cohort 2_7.5 mg/kg IV QW (up to n=6)
Cohort 3_12.0 mg/kg IV QW (up to n=6)
Cohort 4_16.0 mg/kg IV QW (up to n=6)

Up to 40 Patients with Backfill of 4 to 6 Patients per Cohort

FIG. 1

(57) Abstract: Disclosed herein are combined therapies for treating a hematologic malignancy (e.g., acute myeloid leukemia (AML), or myelodysplastic syndromes (MDS)), using an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17), and one or more chemotherapeutics, e.g., a Bcl2 inhibitor such as venetoclax, a hypomethylating agent (HMA), or a combination thereof.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*